Addex Therapeutics Ltd (SWX:ADXN)

Market Cap	2.88M -59.7%
Revenue (ttm)	83.07K -50.3%
Net Income	-6.87M
EPS	-0.06
Shares Out	127.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,361
Open	0.0218
Previous Close	0.0222
Day's Range	0.0208 - 0.0226
52-Week Range	0.0180 - 0.0690
Beta	2.02
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 3
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error